All right. Good morning, everyone. Thank you for joining us on our next fireside session here at the UBS Global Biopharma Conference. I'm Michael Yee, a managing director and senior biotechnology analyst at UBS. I'm very pleased to have SAB Biotherapeutics with us, and joining us up on stage is the Chief Executive Officer, Sam Reich. It's great to see you, Sam.
Thank you for having me. It's a pleasure to be here.
Thank you. Well, maybe I think first and most important is, as people continue to learn more about SAB, that we understand your technology, we understand what makes your product unique. If you could just give us a brief introduction to SAB and specifically your product and what makes it unique, that'd be a great introduction, and we can go into some of the details.
Of course. SAB BIO is a late-stage clinical biopharmaceutical company. Our mission is to transform what it means to get a T1D diagnosis by preserving the patient's ability to make their own insulin. Our drug is in a pivotal phase II-B trial. It is a human anti-thymocyte immunoglobulin, and for treating newly diagnosed type 1 diabetes, again, to preserve the patient's ability to make their own insulin. The mechanism of action is validated by a rabbit anti-thymocyte globulin, which has been tested in multiple clinical trials and proven to preserve C-peptide, which is the marker of the patient's endogenous insulin, and reduce HbA1c, showing improved glycemic control. That rabbit protein leads to an adverse event called serum sickness, which is not well accepted by the clinical community, and the patients certainly don't like it. It also can't be redosed.
It's a one and done, and this is a chronic disease that needs to be redosed. We have solved that problem. Our platform allows us to make a human version of that, and SAB-142 is a human version of anti-thymocyte globulin. We can rely on the efficacy because it's that same clinically validated mechanism of action, and we've solved the safety problem. We've shown in a phase I, we can give the drug safely without causing serum sickness, and we can reliably redose for this chronic condition that needs lifetime dosing.
For those that have been doing work or can be doing work in type 1 diabetes, if you read the data for Thymoglobulin, an antibody that's generated through rabbits, it does work. It is proven efficacious, but there's side effects, and it cannot be redosed.
Correct.
That is a problem. However, it does have statistically significant improvements in C-peptide and A1C.
Yes.
Impressive. But has issues. Can you describe how your product is manufactured? Because I think that's particularly unique, and I'd love to go take a tour.
Yeah, we'd love to have you.
Okay. Tell us about that.
Thymoglobulin, the rabbit version, and SAB-142, the human version, are plasma-derived IgG, and you need a source of the plasma. Thymoglobulin is made by vaccinating rabbits, regular wild-type rabbits, with human thymus, and then that rabbit has an immune response and makes a population of IgG or antibodies that are enriched for targeting thymocytes or T-cells. The plasma's collected from those rabbits, and the IgG is purified from that plasma, and the drug product is purified IgG that's enriched for antibodies that target human thymocytes. But it's rabbit, it's rabbit protein. SAB's proprietary technology is a transchromosomic cow, and that cow makes human antibodies and not bovine antibodies. We vaccinate the cow with human thymus tissue, just like Thymoglobulin.
The cow then becomes a plasma donor, and just so you know, humans donate their plasma on a regular basis, so the cows aren't doing anything humans don't volunteer for. The plasma is then, just like the Thymoglobulin, enriched for antibodies that target T-cells. That becomes the source for manufacturing. We purify the IgG from that plasma, and the drug product, SAB-142, is purified human IgG targeting T-cells.
Fantastic. You have a high throughput site, call it a farm, but it's a site where all of these cows are-
Yeah
-that you're able to make this in a high throughput production that would be supporting commercial production of this product.
Correct.
Fantastic.
Yeah.
So, with this product, can you tell us about the phase I data that you presented earlier this year, and tell us what we learned from that data that has supported the ongoing study, which we'll get into in a moment?
Sure. In phase I, we had several objectives. Objective one was safety, and a key feature of safety was serum sickness. We showed that there is no serum sickness and an acceptable AE profile for outpatient dosing and commercial use. The next objective was to look at the biologic signature to make sure it was similar to Thymoglobulin, and therefore we could rely on the efficacy from Thymoglobulin. The key features of Thymoglobulin that lead to tolerance, this is an autoimmune disease, we're trying to induce tolerance to self, are T-cell exhaustion while preserving Tregs. What we showed in the phase I, that our drug at effective doses induces T-cell exhaustion and preserves Tregs. We could rely on the efficacy.
Another key feature of the phase I was to show redosability. What we showed was that there were no anti-drug antibodies present, detectable, and we did redose and show reliable redosing, both safe and initiating that same mechanism, so we can redose. Lastly, we tested a cohort of patients with T1D. The majority of the trial was done in adult healthy volunteers, and we measured all those things I just mentioned. Then in T1D patients, we looked for efficacy. In those T1D patients, we showed preserved C-peptide. Technically, it was actually increased C-peptide.
We also showed increased time in range. The patients that did well also had T-cell exhaustion. So, we connected the mechanism of action that's proposed to a good clinical outcome, clear signs of therapeutic activity and the desired activity, and really a clinical proof of concept there in patients.
Yeah. Bottom line is this was clear proof of concept on safety, redosing, and efficacy, increase in C-peptide, that basically shows you're on track to do at least what Thymoglobulin is doing, but without the liabilities, without the serum sickness, and the ability to redose.
Correct. Yeah.
Based on that evidence, you've decided to start this pivotal phase II. Can you tell us about the design of the phase II, where you are in that phase II, what the primary endpoints are, and obviously this would be huge if you can hit these. Tell us about the design of the study and what you're doing right now.
Yeah. The phase II-B is called the SAFEGUARD study. It is a pivotal study, so while it's called a phase II-B, it's a phase III. The reason we call it a phase II-B is because it has two active doses, so there is some dose ranging. We like to be technically correct in our terminology, although it's equivalent to a phase III in that we do have alignment with FDA that it can be used to file a BLA and get the drug approved. The study is being conducted in newly diagnosed type 1 diabetes patients that are within 100 days of their diagnosis and have a certain threshold level of C-peptide so that we have something to preserve.
There are three cohorts, a placebo cohort, a higher dose, which is 2.5 mgs per kg, a lower dose, which is 1.5 mg per kg, 1:1 . Both doses are active as demonstrated in our phase I. The primary endpoint, the patients will get dosed at the beginning of the trial and six months, they will get two doses. The primary endpoint is C-peptide to show preservation of C-peptide compared to placebo, and a key secondary endpoint is HbA1c to show a reduction in HbA1c, which means improved glycemic control, and that's at 48 weeks, so a 48-week endpoint.
When would the study complete enrollment? Because data is end of 2027.
Yes. We are looking forward to announcing the last patient randomized this quarter.
Okay.
Looking forward to sharing top-line data from this trial in second half of 2027.
Okay. Primary endpoint is C-peptide.
Yes.
Secondary, key secondary would be A1C. Just to be clear, because a lot of investors are like, "Okay, well, how is that a regulatory endpoint?" People generally want A1C. Can you talk about that and what's happened, and you've engaged with regulators in this new FDA that supports that as an approval endpoint in type 1 diabetes?
Yes. There's been a lot of discussion around what it takes to get a drug approved in type 1 diabetes. The first drug was just approved in June, that's called teplizumab. Now we have a validated regulatory path. We also have our own alignment with FDA from our own communications confirming that it is the validated regulatory path. The question was, what is required? What is sufficient to get a drug approved? Historically, the status quo was that you needed to show a clinical endpoint, not just a lab value. The clinical endpoints could include HbA1c, insulin use, frequency of hypoglycemic events, all things that are clinical signs and symptoms. However, C-peptide is our actual desired effect of the drug, which is easier to prove in a clinical trial because it's an absolute, it's less variable from patient to patient.
There's been a massive lobbying effort with FDA for C-peptide to be sufficient for an approval. Until we saw the teplizumab approval, and shortly before that got our own FDA minutes, that was the status quo. In June, teplizumab was approved having only shown C-peptide. It is an accelerated approval, but it's an approval nevertheless, and the drug has been launched. The thresholds for approval has now been validated to just be easier to achieve than the previous status quo was requiring HbA1c. With that said, in two separate trials of Thymoglobulin, HbA1c was meaningfully reduced with statistical significance. We've designed our trial to be essentially identical to those trials, and so we believe we'll show a reduction on HbA1c. Nevertheless, all that's required for an accelerated approval today at FDA is showing a preservation of C-peptide, which is the primary endpoint.
Tell us about Tzield from Sanofi, because this product was just approved. What is the difference between that product and your product? You said, "Hey, it's really an important data point," is that they validated that C-peptide is an approvable endpoint. It's on the market, sounds good. What is the difference between your drug and that drug?
Yeah. Great question. First of all, Tzield is an incredible accomplishment in the field of type 1 diabetes, and we're thrilled, and the whole T1D community is thrilled that it's been approved. It's a huge step forward for treating these patients in the-
They had a Commissioner's National Priority Voucher, I think, with that product or.
Yeah, they eventually asked to give that, to return that back.
Oh, they had to return that?
Yeah.
Okay.
They didn't want that controversy.
Got it.
Tzield is a monoclonal antibody against T-cells.
Okay.
SAB-142 is a polyclonal. We have, to some extent, a head-to-head between monoclonal and polyclonals because we have data from Tzield, we have data from Thymoglobulin. Tzield, as a monoclonal, when it achieves the dose that induces exhaustion, which leads to tolerance, it is also having some negative impact on Tregs. Tregs are essential for tolerance, and what we see from the Tzield results is a preservation of C-peptide, but they have not yet achieved a reduction in HbA1c or any other clinical endpoint. What we see with Thymoglobulin, or the polyclonal T-cell approach, is both a preservation of C-peptide as well as a reduction in HbA1c. The key difference that we have available to us, it is just a hypothesis, is that when you achieve a dose of the polyclonal that induces exhaustion, Tregs are still preserved.
That is the only sort of detectable or measured difference between the two. So right now, the hypothesis is that if you are able to induce exhaustion while preserving Tregs, you have a superior product. I think if you look at Tzield phase III data, where C-peptide is preserved but HbA1c is not reduced, and you look at Thymoglobulin data, where C-peptide is preserved and HbA1c is reduced, that is enough to conclude that that is superior efficacy. So, there is something different in the polyclonal approach and the monoclonal approach, because they both have the same target, and we believe it is Tregs that lead to superior efficacy. So, we are looking forward to be able to prove that as well in our SAFEGUARD study.
What gives you support, other than the fact that it's a read-through from someone else's drug, Thymoglobulin, that you would be able to show A1C reductions? How likely is that, and how de-risked is that? Appreciate it, and it's like massive upside if you showed that.
Yes.
We do think you'll improve C-peptide.
Yeah.
But as you just explained, while that's nice, A1C would be a huge upside event.
Yes. We have shown in our phase I that we induce exhaustion while preserving Tregs.
Okay.
That is what is the proposed mechanism of Thymoglobulin. We had the study, the key study is called the TN19 study with Thymoglobulin, where those endpoints were hit. We had the raw data, the patient-level data from that. We used that for our statistical modeling. Our trial design is essentially the same. Our statistical modeling is based on the TN19, and we effectively overpowered the study, so we have more patients per group on an absolute basis, and we have another dose. The Thymoglobulin study has one dose, because that drug can only be dosed once, and we are dosing twice throughout the study period. So, we have the same signature mechanism.
Okay.
We have the same study design.
Okay.
More patients and more drug.
Okay. That sounds like a very high probability of success, and part of it is people learning about the story and understanding the story, and understanding the mechanism. If we walk through that, and this is all true, that would be significant upside if you hit that endpoint in the second half of 2027. I mean, just to be clear, you say second half, but when you just take the completion of enrollment and then add 12 months, so it would be like year-end 2027, or?
Well-
It's not July.
There's a couple of things there. One is the actual specific time point for these results is 48 weeks, and another thing is we haven't announced the last patient in yet. So, it could be any day, and when we do that, then we can calculate the actual-
Got it. Okay.
-top line.
Guidance, second half 2027, that was guidance to have a wide range. But again, anyone pretty good at math can add 48 weeks from the last point.
Yeah.
Kind of year-end 2027. Okay. When we are sitting here next year, that would be really
That would be exciting. Yeah.
Okay. All right. If that is the case, can you just walk through a little bit about what are we learning from the type 1 diabetes market? Because Tzield was specifically the first major approval in this setting for type 1 diabetes. If you could just take a little bit of an explanation as to what Tzield setting is approved for, and then what are we learning from that, because that was a big approval, and then how are the sales doing? What are we learning about that?
Yeah. Tzield was approved for a pretty wide age range, although I cannot remember exactly, but let us just say pediatrics to adults.
Okay.
That have been diagnosed with type 1 diabetes within the last eight weeks, or up to eight weeks from diagnosis. That was approved in June. We have recently seen a full quarter of sales, and we are very pleased with what they have achieved because this is the first time that doctors and patients have had the opportunity to intervene or interdict their disease at time of diagnosis. There is a tremendous amount of medical education required and changing the treatment paradigm for newly diagnosed patients, and Tzield is kind of doing the heavy lifting. We expect it to continue to ramp. We are very pleased with how it is going so far. There is a key just sort of base case differentiator between Tzield and our drug, which is that Tzield requires 12 days of continuous dosing.
12 days of continuous dosing.
Yes, and our drug can be given in two days. So, it is already a high hurdle. In addition to 12 days, they have to get prior authorization, which we expect also, and they have eight weeks. So, there is a very limited time window to schedule a 12-day dosing and get prior auth. Now, the majority of payers are reimbursing.
Good to know. What is the price of the drug?
It is currently priced at $356,000.
Okay.
Majority of payers are reimbursing, and it is 12 days of dosing. That is a very difficult logistical burden for the patients and the healthcare provider. In a base case scenario, two-day dosing versus 12-day dosing is a game changer and will make our product best in class.
Certainly if you have an A1C.
All the more so.
Yeah.
Yeah.
And can redose.
Yes.
Okay. Tell us about the PRISE study. What is the PRISE study and how important is that? That is another study going on.
Yeah. So, we mentioned that Tzield requires the patient to be within 56 days or eight weeks of diagnosis. The SAFEGUARD study is within the first 100 days. So, the only drug approved is within the first eight weeks after diagnosis. All the clinical trials limit the drug to some window of time from diagnosis, and there is the thought that that is arbitrary, and if it is, that is what the PRISE is designed to prove. But it is excluding a great number of patients that these endocrinologists are seeing. I have talked to the patients myself on a regular basis, and they, "I got diagnosed a year ago. What about me? I want the drug." Doctors and patients are experiencing this.
The PRISE study, the objective was to show that that time from diagnosis is arbitrary and to make the drug available to as many patients as possible regardless of their time from diagnosis, because every patient should get treatment and we should preserve their beta cells. Breakthrough T1D, the large international organization for patients, patient advocacy group, gave a grant to a consortium of researchers to conduct the PRISE study. We are co-funding the study. It is a phase III, and it has three cohorts. One cohort is within 100 days of diagnosis. The next cohort is from 100 days to one year, and the third cohort is from one year to two years.
The upside there is if the drug works in cohort two or both cohort two and three, the drug will be available to more patients. There will be greater access, less of this sort of time window of pressure.
There is a lot that patients go through when they get diagnosed. They have got this transformational diagnosis. They have to learn how to use insulin and how to measure their blood sugar and how this is changing their life, and then saying you have eight weeks to make a decision about this drug is a lot to put on the patient. With the PRISE study, we say, "We want to intervene quickly. We want to save as many beta cells as possible, but you have time to make that decision." We believe that will just increase market penetration and obviously increase access to a much broader patient population.
How much reduction of insulin use would be expected with this product?
Well, that's a good question. Insulin use is very regimented and very variable from patient to patient. It's not something that has been shown to be proven in a clinical trial yet, although large bodies of research have shown that overall, a patient with more C-peptide uses less insulin. These studies aren't really powered to show a difference, but science knows there's a difference, and that what several large studies have shown is that a patient making their own insulin uses less insulin-
Right.
-than a patient not making their own insulin. And payers have gladly reimbursed this $356,000 drug-
Right.
-which has not shown a reduction in insulin.
Right.
Because they know-
Yeah.
-that overall patients will use less insulin.
Well, and they're preserving beta function.
Yes.
I mean, that's the critical part is that-
Yes.
-you are preserving the function such that, if you do not, we are going to get significantly worse and it is going to get bad, and that would be terrible. Tell me then about the redosing. Tzield is generally not redosed.
It is not thought There is no data to support its redosing. There is no thought that it can be redosed, and over 80% of the patients have anti-drug antibodies after the second dose. It is given at time zero and six months, which is really one course spread out over six months, and it is not thought to be able to be given again. This is a chronic disease. This is an autoimmune disease where patients on a relatively linear level are losing beta cells over time. We need to be able to keep that pharmacologic activity acting perhaps for the life of the patient. There is a real shortcoming and real concern about a drug that can only be given once, because we know that six months or a year after their last dose, they will then go on to continue to lose beta cells.
A huge advantage of SAB-142 is that we can continue to redose the patients and preserve their beta cells, perhaps for their lifetime.
How long is Tzield expected to last then? Because you are dosing one time for $356,000.
Well-
I don't understand the concept of how long that would last for. Yours is redosing.
Yeah.
That's critical. What defines being in the trial, what defines, I guess it is in the protocol to get a second dose. Is that correct?
In our trial?
In your trial.
Our trial, the patients will get a second dose, then there is a long-term extension where they can get a third and a fourth dose.
Right.
We will have a package of four doses for two years.
What defines the need to get a second dose? I guess in your study, you get one and then one after six months. Chronically, what would define whether or not someone needs to get another dose?
If they still have C-peptide. We do have some evidence from Tzield that it wears off, because in their stage two study, patients on placebo progressed. That was in stage two. So, stage two, the patients do not yet need insulin. It is almost like pre-diabetes.
The endpoint was time to progression to stage three. Placebo patients progressed in two years on average, and drug patients progressed in four years on average. You might say, "Oh, it is two years," but it is really not, because patients could be in stage two, early stage two, and years away, two years away, or patients could be in late stage two and any day away.
Okay.
It is just on average two years versus four years. That is proof that it wears off.
Right.
Because they still go on to convert to stage three.
Right. For your drug, what would be expected to be required to get a redose, then how would you price the drug if yours could be chronically, or how would that work?
You measure C-peptide, if the patients still have any amount of C-peptide, they would continue to redose. It's early days for pricing, so we're just doing the work now to price the drug, what we have now, that'll develop over time. Hope to meet you again and have more clarity on pricing. What we have now is the price of Tzield as a guidepost.
Okay. Talk about then, one of the other factors is if this works, how do we have confidence in the commercial manufacturing? Not familiar with bovine manufacturing in terms of FDA-approved drugs. How do I think about that? That's always important. Is that something that is going to be supported by regulatory CMC? Can you talk a little bit about that? That's why I want to take a tour, but
Yeah, yeah.
I'm not an FDA.
You should take a tour.
I'm not an FDA inspector.
It's really fascinating. There's about 40 FDA-approved commercial IgGs that are plasma-derived IgG drugs. About two-thirds of them are human with a human donor, and about one-third are from animals, rabbits, horses, and sheep or goats. FDA has seen and approved IgGs from both humans and animals. That's a well-trodden path at FDA. The same CMC group at FDA that approves Thymoglobulin, which comes from rabbits.
Okay.
Are looking at our IND, and there's a certain accepted sort of standard for what is required to get a drug approved. That's a plasma-derived IgG.
Okay.
It's a well-trodden path. We're not doing anything that hasn't already been done, and the FDA is looking at something that they've seen before and approved before.
Okay. Tell us a little about the balance sheet if all this works. Where are you at the balance sheet, cash burn, et cetera?
I believe we usually have Lucy up for the balance sheet questions, but I believe last quarter we had $200 million, a little more than $200 million on the balance sheet, and that gives us cash through 2028, which is a year post the major catalyst, major value inflection point of top-line data from this study.
Okay. Fantastic. Sam, thank you very much for the conversation. We look forward to completing enrollment.
Yes.
And then to data for 2027.
Thank you for having me.
All right. Thank you, Sam.